Pfizer, a US pharmaceutical company, has found that an experimental drug-type treatment for COVID-19 that they developed reduces the risk of hospitalization and death by 89%.
Pfizer announced that the results of testing an antiviral pill developed for the treatment of COVID-19 showed this effect.
This surpasses the effectiveness of the oral COVID-19 treatment molnupiravir developed by US pharmaceutical company Merck & Company, Reuters reported.
Previously, Merck disclosed that the clinical trial results showed that Molnupiravir had the effect of reducing the hospitalization rate and death rate for COVID-19 by half.
Pfizer said that when the test results showed that the treatment was very effective, an advisory panel of experts recommended that the trial be stopped early, and that it would file an application for approval with the U.S. Food and Drug Administration as soon as possible.
Reuters reported that Pfizer plans to submit the results of an interim study to the FDA as part of an emergency use application.
Pfizer’s tablets, which will be branded ‘Paxrovid’, are administered in combination with ritonavir, an HIV treatment for the human immunodeficiency virus, and three tablets twice a day for a total of six tablets, Reuters explained.
YTN Kim Hyung-geun (hkkim@ytn.co.kr)
[저작권자(c) YTN & YTN plus 무단전재 및 재배포 금지]
.
